Mitsubishi Tanabe Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MITSUBISHI TANABE, and what generic alternatives to MITSUBISHI TANABE drugs are available?
MITSUBISHI TANABE has two approved drugs.
There are five US patents protecting MITSUBISHI TANABE drugs.
There are twenty patent family members on MITSUBISHI TANABE drugs in fourteen countries.
Summary for Mitsubishi Tanabe
| International Patents: | 20 |
| US Patents: | 5 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
| Patent Litigation for Mitsubishi Tanabe: | See patent lawsuits for Mitsubishi Tanabe |
Drugs and US Patents for Mitsubishi Tanabe
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | 10,987,341 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | 11,241,416 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-001 | May 5, 2017 | AP | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
| Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | 11,826,352 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | 11,478,450 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | 11,957,660 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mitsubishi Tanabe
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-001 | May 5, 2017 | 6,933,310 | ⤷ Subscribe |
| Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-002 | Nov 15, 2018 | 6,933,310 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Mitsubishi Tanabe Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2023087011 | ⤷ Subscribe |
| Israel | 282773 | ⤷ Subscribe |
| Brazil | 112021008197 | ⤷ Subscribe |
| Mexico | 2024000663 | ⤷ Subscribe |
| South Korea | 20210087490 | ⤷ Subscribe |
| China | 112969459 | ⤷ Subscribe |
| Argentina | 116967 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
